Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NEA
Biotech
Zenas bags $200M series C to reach a handful of key mAB readouts
Zenas' $200 million series C is the company's second consecutive nine-digit financing.
Max Bayer
May 7, 2024 7:00am
Novo powers transatlantic rare disease fund to $124M first close
Jan 4, 2022 7:40am
Recludix emerges with $60M, Seagen exec Nancy Whiting at helm
Nov 15, 2021 8:00am
Stablix emerges from stables with cash for protein stabilization
Jun 3, 2021 8:00am
NEA-backed Allay exits stealth with clinical pain data
May 13, 2021 8:25am
Arcellx raises $85M to take anti-BCMA cell therapy into humans
Oct 4, 2019 8:28am
